A Large US Health Insurance Claims Database Will be Used to Estimate the Incidence of Serious Outcomes in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis Treated With Golimumab and Other Types of Biological and Systemic Non Biological Treatments

Trial Profile

A Large US Health Insurance Claims Database Will be Used to Estimate the Incidence of Serious Outcomes in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis Treated With Golimumab and Other Types of Biological and Systemic Non Biological Treatments

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs Golimumab (Primary) ; Antipsoriatics; Antirheumatics; Tumour necrosis factor receptor antagonists
  • Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Janssen Biotech
  • Most Recent Events

    • 24 Nov 2017 Planned number of patients changed from 1000 to 400.
    • 24 Nov 2017 Planned End Date changed from 5 Sep 2017 to 1 Jun 2018.
    • 24 Nov 2017 Planned primary completion date changed from 5 Sep 2017 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top